{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-208095","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.134457+00:00","generated_at":"2026-06-11T18:31:56.782933+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cabaletta Bio Q2 2023: cash $176.3M; IND cleared for CABA-201 in myositis","bullets":["Cash, equivalents & investments of $176.3M as of June 30, 2023, extending runway into Q4 2025.","Net proceeds of ~$93.8M from May 2023 public offering of 8,337,500 shares at $12.00/share.","R&D expenses $11.8M (Q2 2023) vs $9.5M (Q2 2022); G&A $4.1M vs $3.5M.","FDA cleared second IND for CABA-201 in myositis; Fast Track designation granted for SLE/LN.","Anticipates initial 3-month clinical data for CABA-201 by first half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-208095","json":"https://secwatch.observer/filing/0001193125-23-208095.json","markdown":"https://secwatch.observer/filing/0001193125-23-208095.md","text":"https://secwatch.observer/filing/0001193125-23-208095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/0001193125-23-208095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/d538476d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:31:56.782933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e75a0370a0a12b36e26863f169da7ec4315c3303","claim":"Cabaletta Bio, Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523208095/0001193125-23-208095-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}